Hospital & Healthcare Services · Founded 2001 · www.maxhealthcare.in · BSE 543220 · NSE MAXHEALTH · ISIN INE027H01010
No Notes Added Yet
Business
Max Healthcare Institute Ltd. is one of India's leading providers of comprehensive, integrated, and high-quality healthcare services. The company operates a chain of super-specialty hospitals primarily focused on tertiary and quaternary care in major metro cities, particularly strong in the Delhi-NCR region. Its core business model involves operating these hospitals, offering a wide spectrum of medical services including diagnostics, consultations, inpatient and outpatient care, complex surgeries, and emergency services. Max Healthcare generates revenue primarily through patient services, including fees for medical procedures, consultations, room charges, diagnostics, and pharmaceutical sales within its facilities. It serves both domestic and international patients, positioning itself as a premium healthcare provider.
Revenue Mix
Max Healthcare's primary business segment is hospital services. Revenue is largely derived from a mix of inpatient (IPD) and outpatient (OPD) services. While specific percentage breakdowns vary by reporting period, inpatient services, including surgeries, critical care, and extended hospital stays, typically constitute the significant majority of its revenue for large hospital chains. Other revenue streams include diagnostics, pharmacy sales, and medical tourism.
Industry
The Indian hospital and healthcare services industry is characterized by robust growth, driven by increasing population, rising disposable incomes, growing health insurance penetration, and a higher incidence of lifestyle diseases. It is a fragmented industry with a mix of public and private players, though consolidation is occurring in the private sector. Max Healthcare is positioned as one of the largest and most reputed private hospital chains in India, particularly prominent in North India. It is known for its super-specialty offerings, advanced medical technology, and highly skilled medical professionals, catering to a premium segment of the market and attracting significant medical tourism.
MOAT
Brand Reputation & Trust: Established brand name synonymous with quality, clinical excellence, and specialized care, particularly in North India. This builds patient trust and preference.
Scale & Network: Operates a large network of hospitals and bed capacity, especially in strategic urban centers like Delhi-NCR, which provides operational efficiencies, strong referral systems, and a wide patient reach.
Clinical Excellence & Talent Pool: Reputation for complex medical procedures, state-of-the-art infrastructure, and ability to attract and retain highly experienced doctors and specialists.
High Capital Intensity: The hospital industry requires significant capital investment for infrastructure, technology, and land, creating high barriers to entry for new competitors.
Switching Costs: For critical and chronic care, patients often develop trust and familiarity with a healthcare provider and their medical team, leading to high perceived switching costs.
Growth Drivers
Increasing Healthcare Expenditure: Rising per capita income and health consciousness are leading to higher out-of-pocket spending and greater health insurance adoption.
Demographic Shifts: India's large and aging population, coupled with a rise in lifestyle-related and chronic diseases, drives demand for specialized medical services.
Medical Tourism: India's position as an attractive destination for high-quality, cost-effective medical treatment, particularly for super-specialty procedures, benefits Max Healthcare.
Expansion & Capacity Addition: Organic growth through brownfield expansion (adding beds in existing facilities) and inorganic growth through acquisitions of new hospitals.
Technological Advancements: Adoption of advanced medical technologies and digital health solutions to improve patient outcomes and operational efficiency.
Government Focus on Healthcare: Increased government spending and initiatives to improve healthcare infrastructure and access.
Risks
Regulatory & Pricing Risks: Potential government intervention in healthcare pricing (e.g., procedure caps, drug price controls) could impact profitability.
Manpower & Talent Retention: High reliance on skilled medical professionals (doctors, nurses). Competition for talent and rising personnel costs can impact margins.
Intense Competition: Competition from other large hospital chains and regional players, potentially leading to pricing pressures.
High Capital Expenditure: Significant capital requirements for facility expansion, maintenance, and technological upgrades can strain financial resources.
Medical Malpractice & Litigation: Risks associated with medical errors, litigation, and reputational damage.
Economic Downturns: Could impact patient affordability for elective procedures and overall healthcare spending.
Infrastructure & Utilities: Reliance on consistent supply of power, water, and other utilities in a capital-intensive environment.
Management & Ownership
Max Healthcare is promoted by Radiant Life Care Private Ltd., led by Abhay Soi, who is the Chairman and Managing Director. Global private equity firm KKR also holds a significant stake in the company, reflecting institutional investor confidence and a professional approach to governance. The management team is generally perceived as experienced in the healthcare sector, with a focus on operational efficiency, quality healthcare delivery, and strategic expansion. The ownership structure includes the promoter group, KKR, other institutional investors (domestic and foreign), and public shareholders.
Outlook
Max Healthcare is well-positioned to capitalize on India's structural healthcare growth drivers, including rising incomes, increasing health awareness, and medical tourism. Its strong brand, extensive network, and focus on super-specialty care provide a durable competitive edge. Successful execution of its expansion plans, coupled with improving operational efficiencies and higher Average Revenue Per Occupied Bed (ARPOB), could drive sustained revenue and profitability growth. However, the company faces inherent risks such as potential regulatory price caps, intense competition for talent and patients, and the high capital expenditure required for continuous expansion and technological upgrades. These factors necessitate careful management of costs and strong execution to maintain its premium positioning and profitability in a dynamic market.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 1335 | 1423 | 1543 | 1707 | 1868 | 1910 | 2028 | 2135 | 2068 | 2143 |
| Other Income | 46 | 44 | 35 | 41 | 33 | 47 | 37 | 33 | 45 | 48 |
| Total Income | 1381 | 1467 | 1578 | 1748 | 1902 | 1957 | 2064 | 2168 | 2113 | 2191 |
| Total Expenditure | 949 | 1040 | 1156 | 1257 | 1369 | 1398 | 1505 | 1560 | 1529 | 1536 |
| Operating Profit | 432 | 427 | 422 | 491 | 532 | 559 | 559 | 608 | 584 | 654 |
| Interest | 11 | 21 | 24 | 34 | 52 | 55 | 55 | 54 | 60 | 67 |
| Depreciation | 61 | 70 | 77 | 84 | 98 | 101 | 104 | 108 | 111 | 123 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | -74 | 0 | 0 | 0 | -48 | 0 |
| Profit Before Tax | 360 | 336 | 321 | 374 | 309 | 403 | 400 | 446 | 365 | 465 |
| Provision for Tax | 70 | 84 | 85 | 92 | 70 | 84 | 92 | -45 | 64 | 122 |
| Profit After Tax | 289 | 252 | 236 | 282 | 239 | 319 | 308 | 491 | 301 | 342 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 289 | 252 | 236 | 282 | 239 | 319 | 308 | 491 | 301 | 342 |
| Adjusted Earnings Per Share | 3 | 2.6 | 2.4 | 2.9 | 2.5 | 3.3 | 3.2 | 5.1 | 3.1 | 3.5 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 1134 | 1434 | 1608 | 1729 | 1691 | 1059 | 2508 | 3937 | 4563 | 5406 | 7028 | 8374 |
| Other Income | 27 | 36 | 42 | 55 | 67 | 53 | 135 | 132 | 152 | 189 | 164 | 163 |
| Total Income | 1161 | 1471 | 1651 | 1784 | 1758 | 1112 | 2643 | 4068 | 4715 | 5595 | 7192 | 8536 |
| Total Expenditure | 1058 | 1331 | 1468 | 1616 | 1546 | 970 | 2124 | 2998 | 3335 | 3925 | 5188 | 6130 |
| Operating Profit | 102 | 140 | 183 | 167 | 212 | 142 | 519 | 1070 | 1380 | 1670 | 2004 | 2405 |
| Interest | 61 | 68 | 100 | 99 | 101 | 83 | 179 | 101 | 84 | 60 | 165 | 236 |
| Depreciation | 78 | 91 | 96 | 94 | 103 | 46 | 174 | 221 | 232 | 245 | 359 | 446 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | -234 | -9 | 0 | 0 | -74 | -48 |
| Profit Before Tax | -37 | -19 | -12 | -26 | 8 | 13 | -69 | 739 | 1064 | 1365 | 1406 | 1676 |
| Provision for Tax | 0 | 4 | -11 | 2 | 9 | -0 | 46 | 134 | -40 | 308 | 330 | 233 |
| Profit After Tax | -37 | -23 | -1 | -29 | -0 | 13 | -115 | 605 | 1104 | 1058 | 1076 | 1442 |
| Adjustments | 0 | 0 | 17 | 8 | -3 | 46 | -23 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | -37 | -23 | 16 | -21 | -3 | 59 | -138 | 605 | 1104 | 1058 | 1076 | 1442 |
| Adjusted Earnings Per Share | -0.8 | -0.4 | 0.3 | -0.4 | -0.1 | 1.1 | -1.4 | 6.2 | 11.4 | 10.9 | 11.1 | 14.9 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 30% | 21% | 46% | 20% |
| Operating Profit CAGR | 20% | 23% | 70% | 35% |
| PAT CAGR | 2% | 21% | 142% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -18% | 21% | 33% | NA% |
| ROE Average | 12% | 14% | 10% | 4% |
| ROCE Average | 15% | 15% | 12% | 8% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 831 | 1145 | 1192 | 1167 | 963 | 2553 | 5639 | 6282 | 7410 | 8408 | 9381 |
| Minority's Interest | 0 | -17 | -73 | -133 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 332 | 649 | 772 | 849 | 890 | 106 | 843 | 629 | 497 | 1061 | 2270 |
| Other Non-Current Liabilities | 7 | 846 | 875 | 944 | 361 | 304 | 1285 | 1520 | 1150 | 1282 | 1722 |
| Total Current Liabilities | 282 | 422 | 380 | 478 | 1140 | 1010 | 777 | 757 | 1046 | 1249 | 1814 |
| Total Liabilities | 1453 | 3045 | 3146 | 3304 | 3355 | 3974 | 8543 | 9189 | 10102 | 12000 | 15186 |
| Fixed Assets | 740 | 2273 | 2244 | 2227 | 2192 | 851 | 6536 | 7018 | 7039 | 8721 | 11497 |
| Other Non-Current Assets | 330 | 482 | 552 | 645 | 715 | 207 | 883 | 1171 | 1120 | 1573 | 2097 |
| Total Current Assets | 383 | 290 | 349 | 432 | 447 | 2915 | 1124 | 1000 | 1943 | 1706 | 1593 |
| Total Assets | 1453 | 3045 | 3146 | 3304 | 3355 | 3974 | 8543 | 9189 | 10102 | 12000 | 15186 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 10 | 25 | 11 | 15 | 9 | 322 | 111 | 627 | 481 | 1374 | 980 |
| Cash Flow from Operating Activities | 64 | 723 | 156 | 82 | 89 | 77 | 118 | 741 | 1284 | 1122 | 1459 |
| Cash Flow from Investing Activities | -194 | -1340 | -104 | -100 | -17 | -2641 | -73 | -764 | -102 | -1285 | -1632 |
| Cash Flow from Financing Activities | 145 | 603 | -48 | 12 | -74 | 2353 | 191 | -294 | -289 | -264 | -164 |
| Net Cash Inflow / Outflow | 16 | -14 | 4 | -6 | -2 | -210 | 236 | -317 | 893 | -428 | -336 |
| Closing Cash & Cash Equivalent | 25 | 11 | 15 | 9 | 8 | 111 | 627 | 309 | 1374 | 980 | 661 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | -0.76 | -0.42 | 0.29 | -0.39 | -0.06 | 1.1 | -1.42 | 6.24 | 11.37 | 10.88 | 11.07 |
| CEPS(Rs) | 0.85 | 1.29 | 1.75 | 1.22 | 1.91 | 1.09 | 0.62 | 8.52 | 13.76 | 13.4 | 14.76 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1.5 | 1.5 |
| Book NAV/Share(Rs) | 17.01 | 21.47 | 22.19 | 21.72 | 17.93 | 47.52 | 58.1 | 64.57 | 75.89 | 85.82 | 95.27 |
| Core EBITDA Margin(%) | 6.64 | 7.22 | 8.73 | 6.52 | 8.6 | 8.37 | 15.3 | 23.84 | 26.9 | 27.4 | 26.19 |
| EBIT Margin(%) | 2.13 | 3.4 | 5.42 | 4.21 | 6.48 | 9.07 | 4.42 | 21.33 | 25.15 | 26.36 | 22.36 |
| Pre Tax Margin(%) | -3.27 | -1.32 | -0.78 | -1.53 | 0.49 | 1.21 | -2.74 | 18.77 | 23.31 | 25.26 | 20.01 |
| PAT Margin (%) | -3.27 | -1.58 | -0.09 | -1.66 | -0.01 | 1.22 | -4.57 | 15.37 | 24.19 | 19.56 | 15.31 |
| Cash Profit Margin (%) | 3.65 | 4.78 | 5.85 | 3.8 | 6.06 | 5.53 | 2.38 | 20.99 | 29.28 | 24.1 | 20.42 |
| ROA(%) | -2.71 | -1.01 | -0.05 | -0.89 | -0.01 | 0.35 | -1.83 | 6.82 | 11.44 | 9.57 | 7.91 |
| ROE(%) | -5.64 | -2.29 | -0.12 | -2.44 | -0.02 | 0.73 | -2.8 | 10.19 | 16.19 | 13.47 | 12.22 |
| ROCE(%) | 2.11 | 3.05 | 4.34 | 3.46 | 5.33 | 3.57 | 2.22 | 12.38 | 15.32 | 16.26 | 14.67 |
| Receivable days | 54.39 | 48.61 | 50.32 | 52.01 | 66.97 | 79.05 | 33.62 | 34.83 | 28.86 | 26.97 | 29.86 |
| Inventory Days | 5.43 | 5.31 | 5.26 | 5.42 | 5.86 | 9.1 | 5.87 | 5.34 | 5.5 | 5.27 | 4.83 |
| Payable days | 162.82 | 170.36 | 185.81 | 205.78 | 279.46 | 395.74 | 188.92 | 173.98 | 195.48 | 191.96 | 178.04 |
| PER(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 55.59 | 38.8 | 75.39 | 99.1 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 0 | 0 | 3.55 | 5.37 | 5.81 | 9.56 | 11.51 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.23 | 0.18 | 0.14 |
| EV/Net Sales(x) | 0.78 | 0.92 | 0.86 | 0.83 | 0.9 | 1.2 | 8.04 | 8.6 | 9.19 | 14.76 | 15.43 |
| EV/Core EBITDA(x) | 8.61 | 9.45 | 7.6 | 8.53 | 7.2 | 8.99 | 38.89 | 31.65 | 30.38 | 47.77 | 54.09 |
| Net Sales Growth(%) | 20.03 | 26.51 | 12.14 | 7.52 | -2.2 | -37.37 | 136.82 | 56.96 | 15.9 | 18.49 | 30.01 |
| EBIT Growth(%) | 1281.86 | 102.36 | 78.7 | -16.41 | 50.37 | -12.38 | 15.4 | 657.85 | 36.65 | 24.19 | 10.26 |
| PAT Growth(%) | 42.69 | 38.97 | 93.81 | -1952.14 | 99.34 | 6894.74 | -986.91 | 628.43 | 82.38 | -4.16 | 1.72 |
| EPS Growth(%) | 49.91 | 44.07 | 169.34 | -231.6 | 85.52 | 2060.71 | -229.69 | 538.21 | 82.14 | -4.25 | 1.7 |
| Debt/Equity(x) | 0.51 | 0.7 | 0.73 | 0.84 | 1.04 | 0.33 | 0.16 | 0.12 | 0.08 | 0.14 | 0.27 |
| Current Ratio(x) | 1.36 | 0.69 | 0.92 | 0.9 | 0.39 | 2.89 | 1.45 | 1.32 | 1.86 | 1.37 | 0.88 |
| Quick Ratio(x) | 1.29 | 0.63 | 0.86 | 0.84 | 0.37 | 2.86 | 1.38 | 1.24 | 1.79 | 1.3 | 0.82 |
| Interest Cover(x) | 0.39 | 0.72 | 0.87 | 0.73 | 1.08 | 1.15 | 0.62 | 8.33 | 13.68 | 23.8 | 9.52 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0.05 | 0.02 | 0.01 | 0.01 | 0.02 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 23.75 | 23.75 | 23.74 | 23.74 | 23.74 | 23.74 | 23.74 | 23.74 | 23.72 | 23.71 |
| FII | 60.68 | 57.32 | 56.97 | 57.29 | 56.93 | 54.74 | 54.76 | 51.8 | 50.55 | 45.39 |
| DII | 11.58 | 14.97 | 15.37 | 15.14 | 15.55 | 17.58 | 17.42 | 20.03 | 21.2 | 26.32 |
| Public | 3.99 | 3.96 | 3.91 | 3.83 | 3.77 | 3.94 | 4.08 | 4.43 | 4.52 | 4.58 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 23.08 | 23.08 | 23.08 | 23.08 | 23.08 | 23.08 | 23.08 | 23.08 | 23.08 | 23.08 |
| FII | 58.97 | 55.71 | 55.37 | 55.7 | 55.35 | 53.21 | 53.24 | 50.36 | 49.18 | 44.17 |
| DII | 11.25 | 14.55 | 14.94 | 14.72 | 15.12 | 17.09 | 16.93 | 19.48 | 20.63 | 25.61 |
| Public | 3.88 | 3.85 | 3.8 | 3.72 | 3.67 | 3.83 | 3.97 | 4.31 | 4.4 | 4.45 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 97.18 | 97.19 | 97.19 | 97.21 | 97.21 | 97.21 | 97.21 | 97.22 | 97.28 | 97.31 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +30% | +21% | +46% | +20% |
| Operating Profit CAGR | +20% | +23% | +70% | +35% |
| PAT CAGR | +2% | +21% | +142% | — |
| Share Price CAGR | -18% | +21% | +33% | — |
| ROE Average | +12% | +14% | +10% | +4% |
| ROCE Average | +15% | +15% | +12% | +8% |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 23.75 | 23.75 | 23.74 | 23.74 | 23.74 | 23.74 | 23.74 | 23.74 | 23.72 | 23.71 |
| FII | 60.68 | 57.32 | 56.97 | 57.29 | 56.93 | 54.74 | 54.76 | 51.8 | 50.55 | 45.39 |
| DII | 11.58 | 14.97 | 15.37 | 15.14 | 15.55 | 17.58 | 17.42 | 20.03 | 21.2 | 26.32 |
| Public | 76.25 | 76.25 | 76.26 | 76.26 | 76.26 | 76.26 | 76.26 | 76.26 | 76.28 | 76.29 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 23.08 | 23.08 | 23.08 | 23.08 | 23.08 | 23.08 | 23.08 | 23.08 | 23.08 | 23.08 |
| FII | 58.97 | 55.71 | 55.37 | 55.7 | 55.35 | 53.21 | 53.24 | 50.36 | 49.18 | 44.17 |
| DII | 11.25 | 14.55 | 14.94 | 14.72 | 15.12 | 17.09 | 16.93 | 19.48 | 20.63 | 25.61 |
| Public | 74.1 | 74.11 | 74.11 | 74.14 | 74.14 | 74.14 | 74.14 | 74.15 | 74.2 | 74.24 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 97.18 | 97.19 | 97.19 | 97.21 | 97.21 | 97.21 | 97.21 | 97.22 | 97.28 | 97.31 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.